Top

Published in:

Open Access 01-11-2010 | Poster presentation

Safety of treatment with biologics for psoriasis in daily practice: 5-year data

Authors: PPM Van Lümig, RJB Driessen, MAM Berends, J B Boezeman, PCM van de Kerkhof, EMGJ de Jong

Published in: Journal of Translational Medicine | Special Issue 1/2010

Excerpt

The safety of biological treatment for psoriasis is an important issue. Concerns exist about a possible increased risk of cancer, including nonmelanoma skin cancer and lymphomas in psoriasis patients treated with TNF-α inhibitors.[1] Dermatological conditions have been shown to be a significant and clinically important problem in rheumatoid arthritis patients receiving TNF-α blocking therapy.[2] …

Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009, 60: 1001-1017. 10.1016/j.jaad.2008.12.031.CrossRefPubMed

Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005, 7: R666-R676. 10.1186/ar1724.PubMedCentralCrossRefPubMed

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM: Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009, 160: 670-675. 10.1111/j.1365-2133.2008.09019.x.CrossRefPubMed

van Weel C: The Continuous Morbidity Registration Nijmegen: background and history of a Dutch general practice database. Eur J Gen Pract. 2008, 14 (Suppl 1): 5-12. 10.1080/13814780802436028.CrossRefPubMed

Title: Safety of treatment with biologics for psoriasis in daily practice: 5-year data
Authors: PPM Van Lümig
RJB Driessen
MAM Berends
J B Boezeman
PCM van de Kerkhof
EMGJ de Jong
Publication date: 01-11-2010
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue Special Issue 1/2010
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-8-S1-P16

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Immunosurveillance by gamma delta T cells - lessons from the cancer field

Efficacy of adalimumab in sarcoidosis

TNF and IL-6 differentially regulate the production of DKK-1, a master regulator of bone remodelling, by fibroblast-like synoviocytes

Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus

Sustained T cell Rap1 activation protects against Experimental Autoimmune Encephalomyelitis (EAE) via modulation of T cell responses

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials